Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,764 signal articles · 251 in last 24h · 118,005 total before filter · latest 49m ago
251last 24h
1622last 7d
251● bullish (7d)
158● bearish (7d)
205publishers
AllMacro307Earnings683M&A92Regulatory28Product13Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Axon Enterprise (AXON) Fairly Valued As Raised 2026 Guidance Meets Margin Pressure?
Simply Wall St.12d agoneutral
Is Axon Enterprise (AXON) Fairly Valued As Raised 2026 Guidance Meets Margin Pressure?

Axon Enterprise (AXON) lifted its 2026 revenue growth outlook to a range of 32% to 34% after reporting Q2 results that exceeded sales estimates but came with margin pressure and an earnings per share miss versus expectations. See our latest analysis for Axon Enterprise. The raised 2026 guidance comes after a sharp rebound in Axon Enterprise’s share price, with a 7 day share price return of 14.74% and a 90 day share price return of 42.77%. That pace contrasts with a 1 year total shareholder...

Symbotic (SYM) Is Up 15.3% After Q3 Profit Return And Higher Revenue Outlook - What’s Changed
Simply Wall St.12d agoneutral
Symbotic (SYM) Is Up 15.3% After Q3 Profit Return And Higher Revenue Outlook - What’s Changed

Symbotic Inc. recently reported third-quarter 2026 results, with revenue rising to US$720.84 million and net income reaching US$11.67 million, alongside the appointment of former Bain Capital Co‑Chair Steve Pagliuca to its Board and new fourth‑quarter revenue guidance of US$760 million to US$780 million. The company’s return to profitability over both the quarter and the nine‑month period, coupled with revenue guidance that points to continued operational momentum, could be especially...

Atlassian (NASDAQ:TEAM) Beats Expectations in Strong Q2 CY2026, Stock Jumps 37.4%
StockStory12d agobullish
Atlassian (NASDAQ:TEAM) Beats Expectations in Strong Q2 CY2026, Stock Jumps 37.4%

Collaboration software company Atlassian (NASDAQ:TEAM) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 27.6% year on year to $1.77 billion. Guidance for next quarter’s revenue was optimistic at $1.71 billion at the midpoint, 2.8% above analysts’ estimates. Its non-GAAP profit of $1.87 per share was 24.5% above analysts’ consensus estimates.

MACOM Technology Solutions Q3 Earnings Call Highlights
MarketBeat12d agoneutral
MACOM Technology Solutions Q3 Earnings Call Highlights

MACOM Technology Solutions (NASDAQ:MTSI) reported record fiscal third-quarter results, citing strong demand across its data center, industrial and defense, and telecom markets. The company also issued fourth-quarter guidance that calls for another sequential increase in revenue, margins and adjusted

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

MKS Q2 Earnings Call Highlights
MarketBeat12d agoneutral
MKS Q2 Earnings Call Highlights

MKS (NASDAQ:MKSI) reported second-quarter 2026 revenue of $1.25 billion, up 16% sequentially and 28% from a year earlier, as demand increased across semiconductor, electronics and packaging, and specialty industrial markets. Management said revenue and key profitability measures reached the high end

Lightbridge Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Lightbridge Q2 Earnings Call Highlights

Lightbridge (NASDAQ:LTBR) reported progress in its nuclear fuel development program during the second quarter and first half of 2026, including the removal of its first irradiated fuel material samples from Idaho National Laboratory’s Advanced Test Reactor and steps toward commercial-scale fabricati

Ligand Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year